Table 1.
Summary of clinical validation study findings.
| Source | Hyperlipidemia | Hypertension | ||
|---|---|---|---|---|
| Vanderbilt | ||||
| Drug repurposing candidates tested | 84 | 94 | ||
| Therapeutic effect & P < 0.05 | 12 | 23 | ||
| Drugs approved for target disease | 5 | 5 | ||
| Drugs approved for other diseases | 7 | 18 | ||
| Therapeutic effect & P < Bonferroni | 6 | 12 | ||
| Drugs approved for target disease | 5 | 4 | ||
| Drugs approved for other diseases | 1 | 8 | ||
| All of Us | ||||
| Drug repurposing candidates tested | 12 | 22 | ||
| Therapeutic effect & P < 0.05 | 5 | 6 | ||
| Drugs approved for target disease | 4 | 2 | ||
| Drugs approved for other diseases | 1 | 4 |
Therapeutic effect means that individuals experienced reductions in biomarker measurements (LDL-C for hyperlipidemia; SBP for hypertension) after exposure to the drug repurposing candidate.
Two-tailed P values were calculated using linear mixed models.
For the clinical validation studies at Vanderbilt, we report both the number of drugs with P < 0.05 and P values that pass Bonferroni significance to correct for multiple comparisons. For the replication studies in All of Us, we report the number of drugs with P < 0.05.
LDL-C low-density lipoprotein cholesterol, SBP systolic blood pressure.